LifeFlower® Breviscapine (Erigeron Breviscapus extract) is a patented and branded ingredient that contains at least 90% of scutellarin as the primary bioactive compound. It is extracted from Erigeron Breviscapus, a medicinal plant that has been used for over 500 years. LifeFlower® Breviscapine is GRAS self-affirmed to be used as an ingredient in food, beverage and dietary supplement. The recommended dosage is 200mg per person per day as dietary supplement, 84mg per person per serving in food and beverage.






BRE-002 Lifeflower® Breviscapine (Erigeron Breviscapus Extract)(Scutellarin ≥98%, HPLC) 

BRE-003 Lifeflower® Breviscapine (Erigeron Breviscapus Extract)(Scutellarin ≥90%, HPLC)


LifeFlower® Breviscapine is a crude extract of several flavonoids from Erigeron breviscapus (Vant.) Hand.-Mazz, standardized to contain more than 90% scutellarin as the main active compound.


Clinical Research - Cerebrovascular Protection

Journal: Chinese Journal of Integrative Medicine on Cardio-/Cerebrovascular Disease Year: 2017; 17: 2192-2195 Authors: Lulie Mei, et al. To evaluate the clinical efficacy of breviscapine in the treatment of acute cerebral infarction and its influence on intelligence level, blood rheology, blood lipids and inflammation indicators, a total of 150 subjects with acute cerebral infarction were randomly divided into the control group and the experimental group. The control group received conventional blood pressure control and nutritional nerve treatment for acute cerebral infarction. In addition to the conventional treatment, breviscapine was added in the experimental group. The clinical effects and neurological function of the two groups were compared using the National Institutes of Health Stroke Scale (NIHSS) score, the Cognitive Assessment Scale (MoCA) score, and hemorheology [plasma viscosity (PV), fibrinogen). (F-PSA), hematocrit (HCT), blood lipid index [total cholesterol (TC), triglyceride (TG), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C)], inflammatory marker C-reactive protein (CRP) levels. Results showed that the clinical efficacy, neurological function NIHSS score and intelligence MoCA score of the experimental group were significantly better than the control group. The improvement of PV, F-PSA, HCT, TC, TG, HDL-C, LDL-C and CRP was better than the control group as well. It was concluded that the use of breviscapine in the treatment of acute cerebral infarction is safe and effective, which can alleviate brain damage caused by blood flow and metabolic disorders after cerebral infarction and improve prognosis. Source

Clinical Research - Visual Field Protection

Journal: Drugs in R&D

Year: 2010; 10(2): 75-82

Authors: Yisheng Zhong, et al.

40 subjects were enrolled in a double-blinded RCT to evaluate the visual field protective effect of Erigeron breviscapus (vant.) Hand. Mazz. (EBHM) extract on glaucoma with controlled intraocular pressure (IOP). The study group was given orally EBHM tablets for 6 months while control group received placebos. After the treatment, mean defect (MD) was significantly decreased and the mean sensitivity (MS) was significantly increased compared with pre-treatment and the control group. The result suggested that EBHM extract may have a partially protective effect on the visual field of glaucoma patients with controlled IOP.


Review & Meta-Analysis - Comprehensive Review

Journal: Pharmacology & Therapeutics

Year: 2018;190: 105-127

Authors: Liping Wang, et al.

This article comprehensively reviewed the clinical trials and pharmacological studies over the past three decades and summarized breviscapine’s effects of anti-oxidant, anti-inflammation, vascular relaxation, anti-platelet, anti-coagulation, neuroprotection, and myocardial protection. Clinically, breviscapine has shown great efficacy in the therapies for cerebrovascular accident, myocardial infarction, glaucoma, and diabetic complications.


Clinical Research - Cognitive Function Support

Journal: Acta Academiae Medicinae Weifang

Year: 2007; 29(5): 428-430

Authors: Jingming Wang, et al.

To investigate the therapeutic effect of breviscapine on vascular dementia, 68 subjects were enrolled and randomly assigned into two groups. The 34 subjects in experimental group were treated with breviscapine 100mg iv for 20 days, while the control group was treated with citicoline 750mg iv for 20 days. Their MMSE, ADL, HDS, WMS were evaluated and the hemorheological indexes were measured in both groups before and after treatment respectively. Results showed significance difference between the two groups, indicating breviscapine is beneficial for functional recovery of the recognition in vascular dementia subjects.


Journal: Hebei Journal of Traditional Chinese Medicine

Year: 2011; 33(7): 1051-1052

Authors: Guoyin Zhang

A total of 75 subjects with Alzheimer’s Disease (AD) were enrolled in an RCT to investigate the therapeutic effect of breviscapine tablet combined with ginkgo leaf tablet on AD. 38 and 37 subjects were randomly assigned into two group and received breviscapine tablet combined with gingko leaf tablet or gingko leaf tablet alone respectively. Symptoms and signs of subjects in both groups were observed before and after treatment, and the syndrome integral before and after treatment was calculated according to Alzheimer’s Disease Assessment Scale. Besides, the severity of dementia before and after treatment was determined referring to the Clinical Diagnosis and Treatment of Neurological Diseases. Compared control group, treatment group that received both breviscapine and gingko leaf tablet showed a significant improvement regarding to the severity of dementia, indicating the efficacy of breviscapine tablets in combination with ginkgo leaf tablets in AD therapy.


Additional studies of breviscapine or scutellarin are documented on the website, NCBI (US National Library of Medicine National Institute of Health). Search using key words: Breviscapine, Scutellarin, Erigeron Breviscapus


The science behind LifeFlower® Breviscapine supports many functional food, beverage and dietary supplement opportunities.

The suggested dosages are:

  • 200mg/day as dietary supplement

  • 84mg/person as food & beverage ingredient


Greenish yellow fine powder, odorless, and tasteless.






  • GRAS (Generally Recognized as Safe) self-affirmed

  • Safe, class 3 (ethyl acetate or ethanol) solvent extraction

  • Prop 65 compliant

  • Non-irradiated

  • Non-GMO


Is LifeFlower® Breviscapine tested for heavy metals?

Every batch of LifeFlower® Breviscapine produced is tested at both our in-house lab and an external lab for heavy metals including lead, arsenic, cadmium and mercury.

Is LifeFlower® Breviscapine non-GMO?

Yes, LifeFlower® Breviscapine is non-GMO.

Is LifeFlower® Breviscapine GRAS?

Yes, LifeFlower® Breviscapine is Self-Affirmed GRAS (Generally Recognized as Safe).

Is LifeFlower® Breviscapine allergen free?

Yes, LifeFlower® Breviscapine is allergen free.

What are the solvents used in manufacturing of LifeFlower® Breviscapine?

Breviscapine/scutellarin is not water-soluble compounds. Thus, it is necessary to use solvents to extract them from the plant. LifeFlower® Breviscapine is manufactured using only ethanol and acetone (Class 3 solvent listed in USP General Chapter <467>).

Should LifeFlower® Breviscapine be taken with meals?

It is advisable to take LifeFlower® Breviscapine 30 to 60 minutes after meals, but there is no harm if taken in the absence of meals.

Does LifeFlower® Breviscapine cause gastrointestinal problems?

Few people may experience gastrointestinal problem initially, although no cases of gastrointestinal conditions arising from LifeFlower® Breviscapine use have been reported.


Interested in Lifeflower® Breviscapine?

We are happy to provide you spec sheets, MSDS sheets, manufacturing flow charts as well as a variety of marketing information.

Please complete the form and one of our experts will be in touch.

Toll Free: 1-888-327-5664
Fax: 1-909-468-2875​


*Disclaimer: These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.
This Website is Not Intended for Consumer Use.

Copyright © 2019 Farlong USA. All rights reserved.